Antibodies

12 May 2015

Aspyrian Therapeutics Inc. Announces FDA Acceptance of an Investigational New Drug Application for RM-1929, a First-in-Class, Precision-Targeted Therapy for Cancer

7 May 2015

Ablynx presents unique nanobody drug inhalation technology at the Respiratory Drug Delivery Europe 2015 Conference

6 May 2015

Long-Term, 7-Year Study of Nulojix® (belatacept) Regimen Demonstrates Statistically Significant Relative Risk Reduction of Death or Graft Loss over Cyclosporine Regimen in Kidney Transplant

6 May 2015

Researchers Present New Data from Phase 2 Clinical Trial of Eculizumab (Soliris®) in Prevention of Acute Antibody-Mediated Rejection (AMR) in Sensitized Deceased-Donor Kidney Transplant Recipients

6 May 2015

Researchers Present New Data from Phase 2 Clinical Trial of Eculizumab (Soliris(R)) in Prevention of Acute Antibody-Mediated Rejection (AMR) in Sensitized Deceased-Donor Kidney Transplant Recipients

5 May 2015

AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy and Safety of HUMIRA® (adalimumab) in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis

5 May 2015

Clazakizumab, an Anti-IL-6 Monoclonal Antibody for the Treatment of Rheumatoid Arthritis, Meets Primary Endpoint in Follow-On Phase 2b Clinical Trial

5 May 2015

Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer

4 May 2015

Generon Received US FDA Clearance to Initiate Phase IIa Study With F-652, a First-in-Class Biologic, to Treat Patients With Acute GvHD

3 May 2015

Luspatercept Data Presented at the 13th International Symposium on Myelodysplastic Syndromes

30 April 2015

Celgene and Acceleron Select Luspatercept to Advance to Phase 3 in Myelodysplastic Syndromes

30 April 2015

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma

29 April 2015

FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS

27 April 2015

Posters at ECCMID 2015 Highlight Preclinical Data from Synthetic Biologics’ Novel SYN-005 Monoclonal Antibody Combination for the Treatment and Prophylaxis of Whooping Cough (Pertussis)

27 April 2015

Novartis announces Phase III study of Arzerra® met primary endpoint of improved progression-free survival in patients with relapsed CLL

25 April 2015

Lilly’s CYRAMZA® (ramucirumab) Receives Fourth FDA Approval

24 April 2015

Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients

23 April 2015

FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*

23 April 2015

Effect of Genzyme’s Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on Slowing Brain Atrophy and MRI Lesion Activity Maintained Through Four Years

23 April 2015

Biotest proves effective protection from Hepatitis B virus reinfection after liver transplantation in “ZEUS” study with subcutaneous hepatitis B immunoglobulin Zutectra®

23 April 2015

Biotest presents new clinical and preclinical results of Civacir® at The 50th International Liver Congress 2015 in Vienna

23 April 2015

Results of Heidelberg Pharma’s research cooperation with M.D. Anderson Cancer Center published in Nature journal

22 April 2015

OncoMed Initiates Dosing in Randomized Phase 2 Clinical Trial of Demcizumab in Pancreatic Cancer Patients

22 April 2015

Acorda Presents Data on First Clinical Study of Remyelinating Antibody for Multiple Sclerosis at American Academy of Neurology Annual Meeting

22 April 2015

OncoMed Presents Data on Clinical and Preclinical Anti-Cancer Stem Cell Programs at American Association for Cancer Research Annual Meeting

22 April 2015

ImmuneXcite Presents New Preclinical Data at AACR Demonstrating Ability of Its Novel Cancer Immunotherapy Approach to Activate a Potent and Precise T-Cell Attack on Tumors

21 April 2015

First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients

21 April 2015

Pfizer Phase 3 Study Of Inotuzumab Ozogamicin Meets Primary Endpoint In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

21 April 2015

Patients With Advanced Breast, Lung, Esophageal, and Colorectal Cancers Respond to Immunomedics’ Novel Antibody-Directed Chemotherapy After Failing Multiple Prior Standard Treatments

21 April 2015

MacroGenics Presents Pre-Clinical Data on its Multivalent DR5 DART at the AACR Annual Meeting

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

c-Met-Targeted Antibody Therapy Pipeline Review

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

DLL3-Targeted Immunotherapy Candidates Pipeline Review

PD-1 Agonists Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

CD73 Inhibitor Pipeline Review